Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.

Fasting state (main study) Both linagliptin and glimepiride tended to numerically reduce SBP and DBP from baseline to week 8, although this did not reach statistical significance (between‐group mean difference SBP 1.5 ± 2.7 mmHg, P = .583; and DBP 0.8 ± 1.6 mmHg, P = .514) (Figure 1 and Appendix S3).

also in 111,027 other papers